
Influenza and Pneumococcal Vaccine Ordering and Immunization Billing Code Information 2019-20

Flu vaccine is available for the 2019-20 season. Providers who have not pre-booked vaccine or need to order additional supply vaccine should contact flu vaccine manufacturers or distributors to confirm what vaccine products are available for purchase. Vaccine distributor information can be found here: <http://www.izsummitpartners.org/ivats/>. Be sure to order enough vaccine to vaccinate all your patients this season. The Advisory Committee on Immunization Practices recommendation is that all people 6 months and older receive an annual flu vaccination.

There are four flu vaccine manufacturers in the United States this season:

- **GlaxoSmithKline** produces Fluarix® quadrivalent vaccine, which is licensed for use in persons 6 months of age and older (0.5 single-dose prefilled syringe), and FluLaval® quadrivalent vaccine for use in persons 6 months of age and older (vial or 0.5 single dose syringe or 5 mL multi-dose). Visit www.gskvaccines.com/.
- **Sanofi Pasteur Inc.** produces Fluzone®, an inactivated quadrivalent influenza virus vaccine in infant formulation (0.25 single-dose syringe for 6 to 35 months), 0.5mL single-dose syringe, a 0.5 mL single dose vial and 5mL multi-dose vial quadrivalent formulations for 6 months and older, a high-dose trivalent formulation (0.5 mL single dose syringe) for adults 65 years and older and Flublok®, a recombinant inactivated quadrivalent influenza vaccine licensed for use in persons 18 years of age and older (0.5mL single dose vial). For information call 1-800-822-2463 or visit www.vaccineshoppe.com.
- **Seqirus** has four vaccine products. Afluria® is an inactivated quadrivalent influenza virus vaccine, a single dose 0.25 prefilled syringe for persons aged 6-35 months, a single 0.5 mL dose prefilled syringe for persons 3 years and older and multi-dose vial injection vaccines for use in persons 6 months of age and older. Flucelvax® is a cell-based quadrivalent inactivated influenza vaccine, indicated for persons 4 years and older and available as a 0.5 mL single-dose syringe. FluAd™ is inactivated trivalent influenza adjuvanted vaccine approved for use in persons 65 years of age and older (0.5 mL single-dose syringe). Visit <http://www.seqirus-us.com/> for more information.
- **AstraZeneca** produces FluMist, a quadrivalent nasal-spray vaccine (0.2mL dose, 0.1mL per nostril) for use in healthy children, adolescents, and adults who are not pregnant, ages 2 through 49 years. Visit <https://www.flumistquadrivalent.com/>

Product availability may change. Contact your distributor for the most up-to-date information.

Recommendation for Receiving Flu Vaccine

The Advisory Committee on Immunization Practices (ACIP) **has recommended an annual dose of flu vaccine for all people age 6 months and older**. However, for the groups prioritized below, it is especially important that these people at highest risk of complications from influenza to receive an annual flu vaccine:

- People age 50 years and older;
- Children 6 months to 59 months of age, especially those younger than 24 months;
- Persons with chronic conditions including: metabolic disease; pulmonary disease; cardiovascular disease; renal disease; sickle cell anemia; conditions that compromise immunity, e.g. HIV/AIDS, cancer treatments; muscle or nerve disorders, e.g. seizure disorders or severe cerebral palsy that can cause breathing or swallowing problems;
- Residents of long-term care facilities;
- Women who are or will be pregnant during influenza season;
- People who are morbidly obese (BMI ≥ 40 kg {88 lbs}/m²);
- Health care workers and household caregivers or contacts of children age 5 years and younger (especially <6 months), adults ≥ 50 years and adults with chronic medical conditions.

Ordering Flu Vaccine

Use the table below to estimate how much flu vaccine to order. Protect your patients; include enough vaccine for you and your staff. Tally the number of patients you have and record it in the right hand column in the chart below. **Note:** Children aged 6 months through 8 years of age who have not received two doses of flu vaccine prior to this season may need to receive a second dose of flu vaccine for the 2019-2020 season, administered at least 4 weeks after the first dose. Consider this in estimating your order.

Type of Health Risk	Tally Number of Patients	Total
Age 6 – 35 months		
Age 3 - 8 years		
Age 9 years -18 years		
Age 50 years and over		
Patients with chronic health problems		
Close contacts of higher risk groups (age ≥ 6 months)		
Health care personnel (<i>including your staff</i>)		
All other patients		
Grand Total		

Additional Information

For more influenza information, visit the New York City Department of Health and Mental Hygiene website at www.nyc.gov/flu or email us at nycflu@health.nyc.gov. Information is also available on the CDC website at <http://www.cdc.gov/flu/>

Pneumococcal Vaccine

Remember to Order and Administer Pneumococcal Vaccine: According to the Centers for Disease Control and Prevention (CDC), about 900,000 Americans get pneumococcal pneumonia each year and about 5-7% die from it. Additionally, the CDC estimates that there were an estimated 3,700 deaths in the United States from pneumococcal meningitis and bacteremia in 2013, and as many as 400,000 hospitalizations from pneumococcal pneumonia are estimated to occur annually. Vaccination rates are especially low in New York City. In 2016, only 61% of people 65 or older had been vaccinated against pneumococcal disease. The Healthy People 2020 coverage goal is 90% for this age group.

Ensure that all adults at high-risk for pneumococcal disease have received pneumococcal polysaccharide vaccine (PPSV) and pneumococcal 13-valent conjugate vaccine, or Prevnar 13[®] (PCV13) as recommended. There is no need to wait until flu vaccine is available to vaccinate your patients against pneumococcal disease. Pneumococcal vaccines can and should be administered throughout the year.

ACIP recommends use of PCV13 in all children aged 2-59 months, people 6 through 64 years with certain health conditions that put them at increased risk for invasive pneumococcal disease. The ACIP continues to recommend routine administration of PPSV23 to all adults aged 65 years and older. In 2019, ACIP updated its guidance for immunocompetent adults aged 65 years and older, and now recommends administration of PCV13 with shared clinical decision making (publication is forthcoming in a future Morbidity and Mortality Weekly Report). For detailed information on who needs PPSV and PCV13 vaccination and timing for administering the vaccines, visit the CDC web page <https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>. Complete recommendations and information about indications for PCV13 and PPSV23, including revaccination and intervals between doses can be found here <http://www.cdc.gov/vaccines/vpd-vac/pneumo/hcp/index.html>

To purchase PPSV, contact your pharmaceutical distributor, visit the Merck website at www.merckvaccines.com or call Merck at 800-637-2579.

Pfizer Inc. markets PCV13. Ordering information is available at <https://www.pfizerpro.com/product/prevnar-13/adult/support/ordering-vaccines-and-customer-service> or by calling 1-800-666-7248.



Billing and Reimbursement Information

All health insurance plans governed by the Affordable Care Act provide flu vaccine as a covered benefit without any out of pocket costs or co-pay. Under the Affordable Care Act, influenza and pneumococcal vaccine are covered benefits; providers can bill for vaccine and administration costs. Contact CMS at 877-267-2323 or www.cms.hhs.gov, or the health plan for information. Click [here](#) for more information on vaccine billing codes.